Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
<!-- Name:DistributionId Value:8750168 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:NYMX
NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made…
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide…
IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New…
NYMOX Provides Current Update
HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today a one-month update to shareholders as…